What's The Path Forward For Ascendis Pharma (ASND)?

Ascendis Pharma A/S (ASND), a clinical-stage biopharmaceutical company focusing on endocrinology rare disease, is all set to report results from a phase II study of TransCon PTH for adult hypoparathyroidism by the end of this month. Full results from this trial are expected in the third quarter.

from RTT - Biotech https://ift.tt/2TzdGVB
via IFTTT